Study identifier:D0520C00017
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I open-label, single-centre, two cohort crossover study to assess the relative bioavailability after oral administration of AZD9668 free base dosed as a suspension compared to AZD9669 tosylate salt dosed as a tablet
Chronic Obstructive Pulmonary Disease
Phase 1
Yes
AZD9668
All
28
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 tosylate salt tablet | Drug: AZD9668 20 mg |
Experimental: 2 free suspension | Drug: AZD9668 20 mg |
Experimental: 3 tosylate salt tablet | Drug: AZD9668 60 mg |
Experimental: 4 free suspension | Drug: AZD9668 60 mg |